Stock Events

Stock Events

Seres Therapeutics 

$4.76
79
-$0.24-4.8% 20:00 Today
+$0.00+0%20:00After hours

Statistics

Day High
4.93
Day Low
4.71
52W High
29.98
52W Low
4.32
Volume
58,201
Avg. Volume
92,223
Mkt Cap
47.81M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-3.93
-1.37
1.19
3.75
Expected EPS
-1.005
Actual EPS
N/A

Financials

721.93%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
789,000Revenue
5.7MNet Income

Analyst Ratings

17.00Average Price Target
The highest estimate is 22.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MCRB. It's not an investment recommendation.
Tesla
16
TSLA
Apple
15
AAPL
NVIDIA
15
NVDA
Microsoft
13
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Synlogic
SYBX
Mkt Cap8.32M
Synlogic operates in the synthetic biotic medicines space, directly competing with Seres Therapeutics in developing treatments for diseases using microbiome engineering.
Regenxbio
RGNX
Mkt Cap707.66M
REGENXBIO is involved in gene therapy, which overlaps with Seres's work on microbiome therapeutics, especially in targeting similar diseases.
Vertex Pharmaceuticals
VRTX
Mkt Cap138.91B
Vertex Pharmaceuticals, with its focus on creating transformative medicines, competes in the cystic fibrosis market where Seres also aims to make an impact through microbiome therapies.
Evelo Biosciences
EVLO
Mkt Cap1,898
Evelo Biosciences focuses on developing microbiome therapeutics, making it a direct competitor in Seres's core market.
Seres Therapeutics
MCRB
Mkt Cap45.8M
Seres Therapeutics is listed as its own competitor due to an error. Please disregard.
Axsome Therapeutics
AXSM
Mkt Cap10.88B
Axsome Therapeutics, while primarily focused on CNS disorders, represents potential competition in the broader biotech space for innovative treatments, including microbiome therapies.
CRISPR Therapeutics
CRSP
Mkt Cap5.75B
CRISPR Therapeutics, with its gene-editing technology, competes in the innovative treatment space, including potential overlaps in disease areas targeted by Seres.

About

Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
Show more...
CEO
Richard N. Kender
Employees
66
Country
United States
ISIN
US81750R2013
WKN
000A413XF

Listings

F
DE
1S90.F
STU
DE
1S90.STU
MU
DE
1S90.MU
BOATS
BOATS
MCRB.BOATS

0 Comments

Share your thoughts

FAQ

What is Seres Therapeutics stock price today?▼
The current price of MCRB is $4.76 USD — it has decreased by -4.8% in the past 24 hours. Watch Seres Therapeutics stock price performance more closely on the chart.
What is Seres Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Seres Therapeutics stocks are traded under the ticker MCRB.
Is Seres Therapeutics stock price growing?▼
MCRB stock has risen by +1.71% compared to the previous week, the month change is a -4.13% fall, over the last year Seres Therapeutics has showed a -75.4% decrease.
What is Seres Therapeutics market cap?▼
Today Seres Therapeutics has the market capitalization of 47.81M
When is the next Seres Therapeutics earnings date?▼
Seres Therapeutics is going to release the next earnings report on November 11, 2026.
What were Seres Therapeutics earnings last quarter?▼
MCRB earnings for the last quarter are 0.47 USD per share, whereas the estimation was -2.19 USD resulting in a +121.51% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Seres Therapeutics revenue for the last year?▼
Seres Therapeutics revenue for the last year amounts to 789,000 USD.
What is Seres Therapeutics net income for the last year?▼
MCRB net income for the last year is 5.7M USD.
How many employees does Seres Therapeutics have?▼
As of August 26, 2026, the company has 66 employees.
In which sector is Seres Therapeutics located?▼
Seres Therapeutics operates in the Health & Wellness sector.
When did Seres Therapeutics complete a stock split?▼
The last stock split for Seres Therapeutics was on April 22, 2025 with a ratio of 1:20.
Where is Seres Therapeutics headquartered?▼
Seres Therapeutics is headquartered in CAMBRIDGE, United States.